Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Thomas Smith
LP
Thomas Smith
Wall Street Analyst
★★★☆☆
#821
on 13Foresight · ranked by our own returns
62%
Success Rate
+20.8%
Average Return
20 of 32 calls profitable · +7.1% vs benchmark
📈 Across the calls we could measure, roughly 62% of Thomas Smith's ratings turned a profit when each position was held for 1 year — averaging +20.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

79 Buy 2 Hold 0 Sell
Thomas's Stock Coverage 38 ratings · 2026-06-20
Company Date Position Consensus Price Target 1-Yr Return
CLYM
Climb Bio
Jun 12, 2026 BUY Strong Buy
+57.9% avg upside
18 analysts
·
IRON
Disc Medicine
Jun 02, 2026 BUY Strong Buy
+20.2% avg upside
21 analysts
+3.1%
XFOR
X4 Pharmaceuticals
Jun 02, 2026 BUY Strong Buy
+491.4% avg upside
15 analysts
$12.00
184.28% Upside
+1.0%
EQ
Equillium
May 28, 2026 BUY Strong Buy
+181.9% avg upside
14 analysts
$6.00
96.63% Upside
-2.5%
RNAC
Cartesian Therapeutics
May 27, 2026 BUY Strong Buy
+228.2% avg upside
19 analysts
+28.6%
ALMS
Alumis Inc.
May 15, 2026 BUY Strong Buy
+63.6% avg upside
11 analysts
$32.00
36.60% Upside
+0.8%
SYRE
Spyre Therapeutics
Apr 13, 2026 BUY Strong Buy
-15.4% avg upside
23 analysts
$106.00
19.92% Upside
+32.1%
VRDN
Viridian Therapeutics
Apr 06, 2026 BUY Strong Buy
+103.7% avg upside
32 analysts
$50.00
200.65% Upside
+15.8%
IMVT
Immunovant
Apr 02, 2026 BUY Strong Buy
+8.9% avg upside
24 analysts
$50.00
41.47% Upside
+41.7%
EVMN
Evommune, Inc.
Mar 06, 2026 BUY Strong Buy
+134.6% avg upside
12 analysts
$52.00
143.47% Upside
-24.3%
AGMB
AgomAb Therapeutics NV ADR
Mar 03, 2026 BUY Strong Buy
+138.5% avg upside
3 analysts
$36.00
227.92% Upside
·
CNTB
Connect Biopharma Holdings
Jan 13, 2026 BUY Strong Buy
+226.3% avg upside
11 analysts
+7.3%
IVA
Inventiva
Jan 11, 2026 BUY Strong Buy
+350.1% avg upside
16 analysts
$12.00
236.10% Upside
-33.6%
KYTX
Kyverna Therapeutics, Inc.
Dec 15, 2025 BUY Strong Buy
+238.7% avg upside
7 analysts
$32.00
296.62% Upside
-25.7%
SE:HNSA
Hansa Biopharma AB
Nov 26, 2025 BUY Strong Buy
+335.3% avg upside
4 analysts
$102.00
216.48% Upside
·
VKTX
Viking Therapeutics
Oct 23, 2025 BUY Strong Buy
+141.1% avg upside
30 analysts
$118.00
288.42% Upside
-12.6%
SABS
SAB Biotherapeutics
Oct 21, 2025 BUY Strong Buy
+161.3% avg upside
13 analysts
+23.3%
ACRS
Aclaris Therapeutics
Oct 15, 2025 BUY Strong Buy
+122.5% avg upside
15 analysts
$7.00
55.65% Upside
+123.8%
ABVX
Abivax SA Sponsored ADR
Oct 08, 2025 BUY Strong Buy
+20.7% avg upside
15 analysts
$115.00
16.03% Upside
+15.8%
MLTX
MoonLake Immunotherapeutics
Oct 01, 2025 BUY Strong Buy
+51.6% avg upside
20 analysts
$14.00
27.09% Downside
+171.8%
ARGX
Argenx Se
Sep 17, 2025 BUY Strong Buy
-15.9% avg upside
46 analysts
$780.00
11.22% Downside
+20.2%
MDGL
Madrigal Pharmaceuticals
Aug 19, 2025 BUY Strong Buy
-5.8% avg upside
31 analysts
+26.7%
CLDX
Celldex
Aug 19, 2025 BUY Strong Buy
+20.6% avg upside
28 analysts
+34.7%
SGMT
Sagimet Biosciences, Inc. Class A
Aug 18, 2025 BUY Strong Buy
+317.2% avg upside
15 analysts
$26.00
289.30% Upside
-8.6%
ELDN
Eledon Pharmaceuticals
Aug 15, 2025 BUY Strong Buy
+302.0% avg upside
10 analysts
$8.00
104.09% Upside
+44.5%
KROS
Keros Therapeutics
Aug 07, 2025 BUY Strong Buy
+139.0% avg upside
21 analysts
$35.00
228.67% Upside
-21.4%
QTTB
Q32 Bio
Apr 16, 2025 HOLD Buy
+345.2% avg upside
24 analysts
+209.2%
PRTCY
PureTech Health
Aug 28, 2024 BUY Strong Buy
+194.2% avg upside
3 analysts
$58.00
234.55% Upside
·
TRVI
Trevi Therapeutics
Aug 08, 2024 BUY Strong Buy
+17.4% avg upside
16 analysts
$6.00
65.10% Downside
+165.0%
IMUX
Immunic
Aug 08, 2024 HOLD Strong Buy
+166.0% avg upside
21 analysts
$5.00
64.74% Downside
-34.9%
MNKD
MannKind
Aug 07, 2024 BUY Buy
+78.6% avg upside
22 analysts
$7.00
77.74% Upside
-31.5%
KYMR
Kymera Therapeutics
Aug 07, 2024 HOLD Strong Buy
+8.9% avg upside
36 analysts
$33.00
63.45% Downside
+1.3%
PLRX
Pliant Therapeutics
Aug 07, 2024 BUY Buy
+1821.1% avg upside
21 analysts
$46.00
3865.42% Upside
-86.6%
SVRN
OceanPal Inc
Mar 15, 2024 BUY Strong Buy
6 analysts
·
DMRA
Damora Therapeutics
Aug 15, 2023 HOLD Strong Buy
+28.3% avg upside
19 analysts
$2.00
90.52% Downside
·
GB:PRTC
PureTech Health
Aug 08, 2022 BUY Strong Buy
+3934.4% avg upside
1 analyst
$5301.22
3934.42% Upside
·
PBYI
Puma Biotechnology
Jan 17, 2019 HOLD Buy
+458.2% avg upside
11 analysts
$21.00
177.79% Upside
-61.8%
TXMD
TherapeuticsMD
Sep 08, 2017 HOLD Buy
+220.5% avg upside
8 analysts
$6.00
207.69% Upside
-7.0%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Thomas Smith — Frequently Asked Questions
How accurate are Thomas Smith's stock ratings?
Based on the calls 13Foresight could measure, about 62% of Thomas's ratings were profitable over a one-year hold, with an average return of +20.8% per rating, or +7.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Thomas ranked on 13Foresight?
Thomas Smith is currently ranked #821 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Thomas cover?
Thomas most recently has ratings on CLYM, IRON, XFOR, EQ, RNAC, ALMS, SYRE, VRDN, IMVT, EVMN, AGMB, CNTB and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.